Literature DB >> 10549287

Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition.

F Poy1, M B Yaffe, J Sayos, K Saxena, M Morra, J Sumegi, L C Cantley, C Terhorst, M J Eck.   

Abstract

SAP, the product of the gene mutated in X-linked lymphoproliferative syndrome (XLP), consists of a single SH2 domain that has been shown to bind the cytoplasmic tail of the lymphocyte coreceptor SLAM. Here we describe structures that show that SAP binds phosphorylated and nonphosphorylated SLAM peptides in a similar mode, with the tyrosine or phosphotyrosine residue inserted into the phosphotyrosine-binding pocket. We find that specific interactions with residues N-terminal to the tyrosine, in addition to more characteristic C-terminal interactions, stabilize the complexes. A phosphopeptide library screen and analysis of mutations identified in XLP patients confirm that these extended interactions are required for SAP function. Further, we show that SAP and the similar protein EAT-2 recognize the sequence motif TIpYXX(V/I).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10549287     DOI: 10.1016/s1097-2765(00)80206-3

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  61 in total

Review 1.  X-linked lymphoproliferative syndrome.

Authors:  D L Nelson; C Terhorst
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome.

Authors:  Bao Q Vuong; Teresita L Arenzana; Brian M Showalter; Julie Losman; X Peter Chen; Justin Mostecki; Alexander S Banks; Andre Limnander; Neil Fernandez; Paul B Rothman
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 3.  Na(+),K (+)-ATPase as a docking station: protein-protein complexes of the Na(+),K (+)-ATPase.

Authors:  Linda Reinhard; Henning Tidow; Michael J Clausen; Poul Nissen
Journal:  Cell Mol Life Sci       Date:  2012-06-14       Impact factor: 9.261

4.  Loops govern SH2 domain specificity by controlling access to binding pockets.

Authors:  Tomonori Kaneko; Haiming Huang; Bing Zhao; Lei Li; Huadong Liu; Courtney K Voss; Chenggang Wu; Martin R Schiller; Shawn Shun-Cheng Li
Journal:  Sci Signal       Date:  2010-05-04       Impact factor: 8.192

5.  SH2 domains recognize contextual peptide sequence information to determine selectivity.

Authors:  Bernard A Liu; Karl Jablonowski; Eshana E Shah; Brett W Engelmann; Richard B Jones; Piers D Nash
Journal:  Mol Cell Proteomics       Date:  2010-07-13       Impact factor: 5.911

6.  Defective B cell responses in the absence of SH2D1A.

Authors:  Massimo Morra; Robert A Barrington; Ana C Abadia-Molina; Susumo Okamoto; Aimee Julien; Charles Gullo; Anuj Kalsy; Matthew J Edwards; Gang Chen; Rosanne Spolski; Warren J Leonard; Brigitte T Huber; Persephone Borrow; Christine A Biron; Abhay R Satoskar; Michael C Carroll; Cox Terhorst
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-17       Impact factor: 11.205

7.  PSD-95 is a negative regulator of the tyrosine kinase Src in the NMDA receptor complex.

Authors:  Lorraine V Kalia; Graham M Pitcher; Kenneth A Pelkey; Michael W Salter
Journal:  EMBO J       Date:  2006-09-21       Impact factor: 11.598

Review 8.  Designing specific protein-protein interactions using computation, experimental library screening, or integrated methods.

Authors:  T Scott Chen; Amy E Keating
Journal:  Protein Sci       Date:  2012-06-08       Impact factor: 6.725

Review 9.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

Review 10.  X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses.

Authors:  Hamid Bassiri; W C Janice Yeo; Jennifer Rothman; Gary A Koretzky; Kim E Nichols
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.